Prevention of mother-to-child transmission of hepatitis B virus: protocol for a one-arm, open-label intervention study to estimate the optimal timing of tenofovir in pregnancy. Issue 9 (13th September 2020)

• Record Type: Journal Article
• Authors: Bierhoff, Marieke; Nelson, Kenrad E; Guo, Nan; Jia, Yuanxi; Angkurawaranon, Chaisiri; Jittamala, Podjanee; Carrara, Verena; Watthanaworawit, Wanitda; Ling, Clare; Tongprasert, Fuanglada; van Vugt, Michele; Rijken, Marcus; Nosten, Francois; McGready, Rose; Ehrhardt, Stephan; Thio, Chloe Lynne
• Is Part Of: BMJ open. Volume 10:Issue 9(2020)
• Publication Date: 2020-09-13
• Subjects: public health -- tropical medicine -- fetal medicine -- maternal medicine -- therapeutics -- virology; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2020-038123
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Hepatitis B virus (HBV) remains a public health threat and the main route of transmission is from mother to child (MTCT). Tenofovir disoproxil fumarate (TDF) treatment can reduce MTCT of HBV although the optimal timing to attain undetectable HBV DNA concentrations at delivery is unknown. This protocol describes the procedures following early initiation of maternal TDF prior to 20 weeks gestation to determine efficacy, safety and feasibility of this approach in a limited-resource setting. Methods and analyses: One hundred and seventy pregnant women from the Thailand–Myanmar border between 12 and <20 weeks gestational age will be enrolled into a one-arm, open-label, TDF treatment study with cessation of TDF 1 month after delivery. Sampling occurs monthly prenatal, at birth and at 1, 2, 4 and 6 months post partum. Measurement of tenofovir concentrations in maternal and cord plasma is anticipated in 10–15 women who have detectable HBV DNA at delivery and matched to 20–30 women with no detectable HBV DNA. Infant HBsAg status will be determined at 2 months of age and HBV DNA confirmed in HBsAg positive cases. Adverse events including risk of flare and adherence, based on pill count and questionnaire, will be monitored. Infants will receive HBV vaccinations at birth, 2, 4 and 6 months and hepatitis B immunoglobulin at birth if the mother is hepatitis B e antigen positive. Infant growth and neurodevelopment at 6 months will be compared with established local norms. Ethics and dissemination: This study has ethical approval by the Ethics Committee of the Faculty of Tropical Medicine, Mahidol University (FTM ECF-019-06), Johns Hopkins University (IRB no: 00007432), Chiang Mai University (FAM-2559-04227), Oxford Tropical Research Ethics Committee (OxTREC Reference: 49-16) and by the local Tak Community Advisory Board (TCAB-02/REV/2016). The article will be published as an open-access publication. Trial registration number: NCT02995005, Pre-results.